Cogent Biosciences Files 8-K: Material Agreement & Financial Obligation
Ticker: COGT · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, 8-k
TL;DR
Cogent Biosciences just filed an 8-K detailing a material agreement and a new financial obligation. Big news incoming.
AI Summary
On June 11, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction. This filing also indicates the creation of a direct financial obligation or an off-balance sheet arrangement for the registrant, along with a Regulation FD disclosure and financial statements/exhibits.
Why It Matters
This filing signals a significant development for Cogent Biosciences, potentially involving new debt, equity, or a strategic partnership that could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and a financial obligation, which could represent significant opportunities or risks depending on the specifics of the agreement.
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- June 11, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-38443 (identifier) — SEC File Number
- 46-5308248 (identifier) — I.R.S. Employer Identification No.
- 275 Wyman Street (address) — Business Address
FAQ
What is the nature of the material definitive agreement entered into by Cogent Biosciences, Inc. on June 11, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text excerpt.
What type of financial obligation has Cogent Biosciences, Inc. created?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant, but the exact nature is not detailed in the excerpt.
What is the filing date for this 8-K report?
The filing date for this 8-K report is June 11, 2025.
What is Cogent Biosciences, Inc.'s SEC file number?
Cogent Biosciences, Inc.'s SEC file number is 001-38443.
What is the primary business classification for Cogent Biosciences, Inc. according to its SIC code?
Cogent Biosciences, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Cogent Biosciences, Inc. (COGT).